Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 11/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351170 | 1.00 | NAMPT (0.46) | NAMPTCYP2C9EPHX2DRD4SIGMAR1 | |
| SCHEMBL6351165 | 1.00 | NAMPT (0.46) | NAMPTCYP2C9EPHX2DRD4SIGMAR1 | |
| SCHEMBL6351436 | 0.89 | DRD4 (0.48) | NAMPTCYP2C9EPHX2DRD4SIGMAR1 | |
| SCHEMBL6351432 | 0.89 | DRD4 (0.48) | NAMPTCYP2C9EPHX2DRD4SIGMAR1 | |
| SCHEMBL6349707 | 0.88 | DRD4 (0.58) | NAMPTCYP2C9EPHX2DRD4DRD2 | |
| SCHEMBL6349712 | 0.88 | DRD4 (0.58) | NAMPTCYP2C9EPHX2DRD4DRD2 | |
| SCHEMBL6352358 | 0.88 | DRD4 (0.58) | NAMPTCYP2C9EPHX2DRD4DRD2 | |
| SCHEMBL6360058 | 0.85 | CYP2C9 (0.52) | NAMPTCYP2C9EPHX2DRD4SIGMAR1 | |
| SCHEMBL6351411 | 0.79 | DRD4 (0.52) | NAMPTCYP2C9EPHX2DRD4DRD2 | |
| SCHEMBL6351409 | 0.79 | DRD4 (0.52) | NAMPTCYP2C9EPHX2DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | claimed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | NAMPT 2899/4885CYP2C9 290/4885EPHX2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.